Adult Dosing

Pediatric Dosing

Clousure of patent ductus arteriosus (PDA)

• 10 mg/kg (birth weight) IV, followed by two 5 mg/kg doses, after 24 and 48 hours, for a total of three doses

• If closure or size reduction of ductus is seen after completion of first course, no further doses are necessary
• If ductus ductus arteriosus remains open after the first course, a second course may given, or alternative pharmacological therapy or surgery may be considered

• Clousure of a clinically significant patent ductus arteriosus (PDA) in premature infants (32 weeks gestational age) weighing between 500 and 1500 grams refractory to regular medical management

• Hypersensitivity to any of the ingredients of the product
• Pretem infants with proven or suspected untreated infection
• Pretem infants with congenital heart disease requiring patency of the PDA for satisfactory pulmonary or systemic circulation
• Pretem infants with impaired renal function
• Pretem infants with thrombocytopenia, coagulation abnormalities, or bleeding
• Pretem infants with proven or suspected necrotizing enterocolitis

Renal Dose Adjustment

• Anuria or marked oliguria (<0.6 mL/kg/hr): Withhold therapy until renal function normalizes

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Ibuprofen has not been evaluated in infants beyond 36 weeks post-conceptual age, hence its effect on neurodevelopmental outcome and growth, and diseases of prematurity is not clearly known
• Ibuprofen may mask typical signs of infection. Physicians must use the drug cautiously in patients with controlled infection and in infants at risk of infection
• Ibuprofen is a platelet aggregation inhibitor. Preterm infants should be monitored for signs of bleeding
• Ibuprofen can prolong bleeding time, The effect is more prominent in patients with underlying hemostatic defects
• Ibuprofen should be used cautiously in patients with elevated total bilirubin, due to its tendency to displace bilirubin from albumin binding-sites
• Extravascular injection or leakage should be avoided during administration, as tissue irritation may occur

Pregnancy Category:N/A

Breastfeeding: N/A

• CV: Intraventricular hemorrhage, tachycardia, cardiac failure, hypotension
• CNS: Convulsions
• GI: Non-necrotizing enterocolitis, abdominal distension, gastroesophageal reflux, gastritis, ileus, feeding problems, inguinal hernia
• GU: Renal Failure, renal insufficiency/impairment, decresed renal output, hematuria, urinary tract infection, thrombocytopenia
• HEMA: Anemia, bleeding, ventricular hemorrhage
• METABOLIC: Hypoglycemia, hypocalcemia, hypernatremia, hyperglycemia
• DERM: Skin Lesion/irritation
• RESP: Apnea, respiratory infection, respiratory Failure, atelectasis
• LABTESTS: Elevated blood creatinine, elevated blood urea, neutropenia
• HEPA: Cholestasis, jaundice
• LOCAL: Injection site reactions
• MISC: Edema, sepsis, infections

• NSAID; The exact machanism of action for closure of a patent ductus arteriosus in neonates not known. Inhibits prostaglandin synthesis in adults
• Metabolism in neonates is unknown. Metabolized by liver in adults; CYP2C9
• Excertion in neonates is unknown. Primarily excreted in urine in adults (10-15% unchanged)
• Half-life: Unknown in neonates; 2-4 hours in adults

US Trade Name(s)

• NeoProfen

US Availability

NeoProfen

• INJ: 10 mg/mL (2 mL vial)

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Neurologic

Multiple Sclerosis Agent